Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1991;33(4):217-22.
doi: 10.1007/BF01744940.

Comparison of transforming growth factor beta and a human tumour-derived suppressor factor

Affiliations
Comparative Study

Comparison of transforming growth factor beta and a human tumour-derived suppressor factor

S S Somers et al. Cancer Immunol Immunother. 1991.

Abstract

Serum-free supernatants from the human melanoma cell line G361 contain a factor that can potently suppress the generation of tumouricidal lymphokine-activated killer (LAK) cells in response to interleukin-2. To characterise the suppressive factor of tumour origin we performed a number of physicochemical and functional comparisons with another immunosuppressive protein, transforming growth factor beta (TGF beta). The bioactivity of tumour-derived suppressor factor (TDSF), assayed by suppression of LAK cell generation, was unaffected by a reducing agent but lost when denatured with a chaotropic agent. In contrast, TGF beta was inactivated by reduction but not denaturation. TDSF lost bioactivity in conditions of pH less than 4, whereas TGF beta showed no loss of activity. The TDSF moiety has an estimated pI of 4.3 and a molecular mass of 69-87 kDa. This differs from published values of pI 9.5, and 25 kDa molecular mass for TGF beta. Anti-TGF beta antiserum reversed the effects of TGF beta but did not affect the suppression of LAK cell generation caused by TDSF. These findings provide compelling evidence that the TDSF moiety is not TGF beta, and may be a novel immunoregulatory cytokine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Anzano MA, Rieman D, Pritchett W, Bowen-Pope DF, Greig R. Growth factor production by human colon carcinoma cell lines. Cancer Res. 1989;49:2898. - PubMed
    1. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets; identification of a major storage site, purification and characterization. J Biol Chem. 1983;258:7155. - PubMed
    1. Childs CB, Proper JA, Tucker RF, Moses HL. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA. 1982;79:5312. - PMC - PubMed
    1. DeFries RU, Golub SH. Characteristics and mechanism of IFN-gamma induced protection of human tumor cells from lysis by lymphokine-activated killer cells. J Immunol. 1988;140:3686. - PubMed
    1. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, Moses HL, Chen EY. A new type of transforming growth factor-β, TGFβ3. EMBO J. 1988;7:3737. - PMC - PubMed

Publication types

MeSH terms

Substances